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Abstract
Background: Melanoma is the most deadly form of skin cancer without effective treatment. Methylthioadenosine
(MTA) is a naturally occurring nucleoside with differential effects on normal and transformed cells. MTA has been
widely demonstrated to promote anti-proliferative and pro-apoptotic responses in different cell types. In this study
we have assessed the therapeutic potential of MTA in melanoma treatment.
Methods: To investigate the therapeutic potential of MTA we performed in vitro proliferation and viability assays
using six different mouse and human melanoma cell lines wild type for RAS and BRAF or harboring different
mutations in RAS pathway. We also have tested its therapeutic capabilities in vivo in a xenograft mouse melanoma
model and using variety of molecular techniques and tissue culture we investigated its anti-proliferative and pro-
apoptotic properties.
Results: In vitro experiments showed that MTA treatment inhibited melanoma cell proliferation and viability in a
dose dependent manner, where BRAF mutant melanoma cell lines appear to be more sensitive. Importantly, MTA
was effective inhibiting in vivo tumor growth. The molecular analysis of tumor samples and in vitro experiments
indicated that MTA induces cytostatic rather than pro-apoptotic effects inhibiting the phosphorylation of Akt and
S6 ribosomal protein and inducing the down-regulation of cyclin D1.
Conclusions: MTA inhibits melanoma cell proliferation and in vivo tumor growth particularly in BRAF mutant
melanoma cells. These data reveal a naturally occurring drug potentially useful for melanoma treatment.
Background
Melanoma is a common skin cancer resulting in high
morbidity and mortality. The development of effective
therapeutics designed to target melanoma has become
the recent focus of research to improve the melanoma
patient’s prognosis.
In mammalian cells, 5’-Methylthio-5’deoxyadenosine
(MTA) is formed from decarboxylated S-adenosyl-
methionine in the biosynthesis of spermidine and sper-
mine, and is cleaved by MTA phosphorylase (MTAP)
into adenine and 5’-methylthio-5’deoxyribose-1-phos-
pate, which are used for the salvage of ATP and methio-
nine respectively [1].
The MTAP gene lies on 9p21, close to the gene
CDKN2A that encodes the tumor suppressor proteins
p16INK4A and p14ARF being widely expressed in normal
cells and tissues [2]. The INK4A-ARF locus on chromo-
some 9p21, (encoding p16INK4a and p14ARF), is often
deleted in human melanoma [3]. Interestingly, MTAP
and CDKN2A are frequently homozygously co-deleted
otherwise, inactivated in tumor cells including mela-
noma [4], resulting in higher intra and extracellular
MTA levels [5]. A wide variety of biological responses
to MTA have been reported both in vivo and in cell cul-
ture. While physiological intracellular concentrations of
MTA in the nM range might have a tumor-supporting
role in MTAP deficient-melanoma cells [5], the adminis-
tration of higher concentrations of MTA (μM) interfere
with cell proliferation, lymphocyte activation, tumor
development, invasiveness and the regulation of apopto-
sis [6-10]. Moreover, it has been shown that MTA has a
differential effect in normal and transformed cells.
While hepatocarcinoma cells undergo apoptosis when
treated with MTA, normal hepatocytes and normal
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human fibroblast remain viable and are protected from
okadaic acid-induced programmed cell death [5,10,11].
Importantly, MTA has been tested in mice and rats and
found to be non-toxic at high doses even when given
over extended periods [12,13].
Although the mechanisms of action of MTA are not
fully understood, it has been postulated that the inhibi-
tion of polyamine synthesis could be responsible for the
cytostatic effects of MTA. Moreover, MTA has been
shown to interfere with key cell signaling pathways,
being able to inhibit growth-factor induced protein tyro-
sine phosphorylation and to increase intracellular cAMP
levels through the inhibition of cAMP phos-phodiester-
ase [14,15]. Additionally, MTA inhibits protein methyla-
tion, modulating cell signaling and protein expression
[9,16,17].
A number of studies have demonstrated the effects of
MTA in tumoral cell lines. However, in vivo studies
have been restricted to gastroenterological tumor mod-
els or brain autoimmune disease. Besides the continuous
efforts from the scientific community, there are not
effective therapeutic approaches for melanoma treat-
ment. In this study we explored the therapeutic proper-
ties of MTA in melanoma treatment. We used several
human and mouse melanoma cell lines having different
mutational status respect RAS, and BRAF proteins, and
investigated the inhibition capabilities of MTA in vitro.
We also performed in vivo studies using a mouse mela-
noma xenograft model showing the effectiveness of
MTA in melanoma treatment.
Materials and methods
Cell lines
37-31E mouse melanoma cells were described previously
[18-20]. UACC903 cells were a gift from J. Trent (P.
Pollock, Tgen, Phoenix, AR, USA). SkMel147 and
SKMel103 cells were obtained from M. Soengas (CNIO
Madrid, Spain) and MeWo and SKMel28 cells were pur-
chased from the ATCC. 37-31E, SkMel147, SKMel103
and MeWo cells were maintained in DMEM with 10%
FBS, penicillin/streptomycin. 37-31E cells were supple-
mented with EGF (50 ng/ml) (Invitrogen, Carlsbad, CA,
USA) and Insulin (4 μg/ml) (Invitrogen, Carlsbad, CA,
USA) and grown at 37°C and 5% CO2 conditions.
UACC903 were maintained in RPMI medium with 10%
FBS, penicillin/streptomycin (Invitrogen, Carlsbad, CA,
USA).
Antibodies and Western Blot analysis
Cells were lysed in RIPA buffer containing phosphatase
and protease inhibitors (Sigma-Aldrich, Saint Louis,
MO, USA). Liquid nitrogen frozen tumor samples were
homogenized in RIPA buffer. 50 μg of total protein
lysates were separated by SDS-PAGE and transferred to
a membrane. After blocking, membranes were blotted
against different primary antibodies and developed using
horseradish peroxidase linked secondary antibodies and
ECL (GE Healthcare, Barcelona, Spain). Cyclin D1 anti-
body was from Santa Cruz; phospho-Erk1/2 (Thr202/
Tyr204), cleaved-caspase-3, p-S6 (Ser235/236), and
phospho-Akt (Thr308) antibodies were from Cell Signal-
ing (Danvers, MA USA); p-Bad was from Genscript, Pis-
cataway, NJ, USA, Ki67 was from Master diagnostica,
(Granada, Spain) and GAPDH was from Trevigen
(Gaitherburg, MD, USA). CD31 antibody was from
DAKO (Spremberg, Denmark). The anti-MTAP anti-
body was the generous gift of Dr. D.A. Carson (Univer-
sity of California San Diego, CA, USA), and was used at
a 1:1.000 dilution.
Proliferation assays
Cells were seeded one day before treatment (50,000 cells
per well (37-31E, MeWo, SkMel103, SkMel147,
UACC903,) or 75,000 cells per well (Colo829)). Time
point treatments were done in triplicates. Number of
viable cells at different time points was analyzed by
using Guava-Viacount reagent (Guava Technologies,
Hayward, CA, USA), in a cell counter (Viacount; Guava
Technologies, Hayward, CA, USA).
Cell cycle analysis
Cells were grown in complete media and treated for 48
h with 10 μM of MTA. Time point treatments were
done in triplicates. Then, medium and cells were recol-
lected and after centrifugation, cells were fixed and
stained with the Cell Cycle Analysis Guava-Viacount
reagent (Guava Technologies, Hayward, CA, USA). Sam-
ples were analyzed with the Guava cytometer PCA
(Guava Technologies Hayward, CA, USA).
In vivo studies
Five to six month old male FVB/N mice were injected
subcutaneously with one million cells in PBS. When
tumors reached between 50-100 mm3, mice were treated
with either DMSO or MTA (96 μmol/kg body weight), a
dose selected for its previously shown efficacy and lack
of toxicity in other in vivo models [13,21]. MTA was
prepared from S-adenosylmethionine (Europharma,
Madrid, Spain) as described elsewhere [22]. Treatments
were done by IP injection daily. Control mice were trea-
ted with the same volume of DMSO (100 μl). Tumor
size and mice weight was monitored every two days.
Tumor volume was calculated with the equation (d2*D)*
(π/6) (d = small-diameter; D = big-diameter). When
mice were sacrificed, tumors were dissected and pro-
cessed. All the animal procedures have been approved
and supervised by the animal care and ethical commit-
tee of the Vall d’Hebron Research Institute.
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Immunohistochemistry, Immunofluorescence, TUNEL
assay and microvessel density quantification
Paraffin-embedded tumor samples were subjected to
immunocytochemistry according to the manufacturer’s
antibody protocol. Samples were developed either by
using secondary antibodies linked to horseradish peroxi-
dase (HRP) and diaminobenzidine (DAB) as a substrate
or by immunofluorescence. Tumor samples were used
to perform a TUNEL assay as described previously [23].
Apoptosis and proliferating cells were quantified by cal-
culating the average of positive cells in ten fields (10×).
For microvessel quantification, tumor samples were
stained for CD31. Then, the integrated density of CD31
fluorescence per field (20× magnification = 587590 μm2)
was measured using ImageJ software (NIH). Ten fields
per sample were quantified for a total of 5 DMSO trea-
ted tumor samples and 5 MTA treated tumor samples.
Colony formation assays
Three hundred cells were seeded. Treatments were
added next day. Plates were incubated at 37°C and 5%
CO2 until differences between the treatment conditions
were noticeable. Media was changed every 2 days. Plates
were washed with PBS, fixed with 4% formaldehyde
(Sigma-Aldrich, Saint Louis, MO, USA) in PBS for 10
minutes, and stained with crystal violet. Finally, repre-
sentative pictures were taken and the number of clones
was quantified. At least two biological replicates with
three technical replicates each were performed for every
cell line.
Motility assays
For motility assays 5 × 104 cells were seeded in a 24
multi-well plate trans-wells (Corning). Following treat-
ment cells were washed with 1× PBS and fixed with 1%
glutaraldehyde in PBS. Cells were then stained with an
aqueous solution of 0.1% crystal violet. After destaining
in water, non-migrating cells in the top of the trans-well
were removed, and stained migrating cells in the bottom
of the trans-well were destaining with PBS containing
0.2% Triton X-100. The O.D. was then measured at
590 nm[24].
mRNA samples and qRT-PCR
Fresh tumor tissues were disrupted using a rotor-stator
homogenizer. mRNAs from tumors and cell lines were
purified using RNeasy Kit (Quiagen). Amount and qual-
ity of RNA was assessed by spectrometrical measure-
ments. Two hundred ng of RNA per sample were used
to obtain cDNA using SuperScript™ III First-Strand
Synthesis System for RT-PCR following the manufac-
turer’s recommendations (Invitrogen, Carlsbad, CA
USA). qRT-PCR was performed using validated Taqman
Probes (VEGF: Mm 01281447_m1, and 18 S RNA: Hs
03003631_g1); (Applied Biosystems, Foster City, CA
USA). qRT-PCR was performed according to manufac-
turers recommendations in a SDS 7900HT System. 18 S
RNA was used as an internal control. Results were cal-
culated using ΔΔCt method.
Statistics
Comparisons protein expression and tumor size among
cell lines or treatment groups were done by two-sided t
test (Microsoft Excel, Microsoft, Redmond, WA, USA).
Clonogenic assays were analyzed using Wilcoxon
Signed-Rank Test [25](Vassar Stats, Poughkeepsie, NY
USA).
Results
Methylthioadenosine (MTA) inhibits melanoma cell
proliferation
To investigate the inhibition capabilities of methylthioa-
denosine (MTA) on melanoma cells, we performed cell
proliferation assays. Melanoma cell lines harboring wild
type NRAS and BRAF (37-31E and MeWo), NRASQ61L
mutation (SKMel 103 and SKMel 147) or BRAFV600E
mutation (UACC903, Colo 829) were grown in complete
medium and in the presence of increasing concentra-
tions of MTA. Wild type NRAS and BRAF melanoma
cells (37-31E, MeWo) (Fig 1A), and melanoma cells har-
boring NRASQ61L (SKMel 147 and SKMel 103) (Fig 1B)
showed a 50% inhibition of cell proliferation at 9.8 ± 0.4
μM, 18.9 ± 1.2 μM, 10.01 ± 0.2 μM and 21.2 ± 0.2 μM
respectively, while the GI50 for BRAFV600E mutant cell
lines was 6.1 ± 0.4 for UACC903 cells and 8.2 ± 0.3 for
Colo 829 cells (Fig 1C). BRAFV600E mutant cells showed
a significant lower proliferation rate (p < 0.05) at 96 h
using 10 μM MTA compared with wild type or
NRASQ61L mutant cells (Fig 1D). All melanoma cell
lines were significantly (p < 0.01) more sensitive than
normal MEFs (GI50>600 μM) (additional file 1, panel
A), reaching the maximum inhibition of proliferation
between 10 μM and 600 μM concentration of MTA
depending on the cell line (Fig 1). Moreover, cells har-
boring deletions in p16INK4a showed lower levels of
MTAP, and 3 out of 4 of these cell lines appeared to be
more sensitive to MTA treatment (Fig 1E).
These results indicate that MTA is effective inhibiting in
vitro melanoma cells proliferation. Interestingly, the
results also suggest that BRAF mutant cells and prob-
ably cells showing low levels of MTAP would be more
sensitive to the MTA treatment.
MTA reduces melanoma cells survival
We next investigated whether MTA interferes with
melanoma cells survival capabilities. To that end, we
performed clonogenic assays in several melanoma cell
lines adding increasing concentrations of MTA (1 μM
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Figure 1 Methylthioadenosine inhibits melanoma cell growth. Proliferation assays of (A) 37-31E and MeWo (wild type RAS BRAF), (B)
SKMel147 and SKMel103 (NRASQ61L mutated) and (C) UACC903 and Colo829 (BRAFV600E mutated) melanoma cells in complete medium with
increasing concentrations of Methylthioadenosine (MTA). Medium was changed adding fresh MTA every 48 h. Proliferation assays were
performed by counting the number of viable cells using Guava-Viacount reagent (Guava Technologies) in a cell counter (Viacount) at the time
points indicated. Asterisk indicate p < 0.05. (D) Graph showing the percentage of cell proliferation inhibition at 96 h treated with 10 μM MTA.
p-values were calculated performing a t-student test. (E) Western-blot showing the levels of MTAP in the different cell lines. The mutational
status of CDK2NA for the different cell lines is showed in the table.
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to 1 mM). Interestingly, 1 μM concentration of MTA
promoted an increase in the number of colonies in 37-
31E cells, with no detectable effects in the other of cell
lines tested except for the BRAFV600E mutant cell line
Colo829 where 1 μM of MTA totally suppressed the
colony formation. At 10 μM of MTA BRAFV600E mutant
cell lines were significantly more sensitive (p < 0.02)
than RASQ61L mutant cell lines. The addition of 100 μM
of MTA, or higher concentrations, was very effective
inhibiting melanoma cell viability, independently of the
RAS pathway mutational status (Fig 2). Altogether, the
results showed that at 100 μM or higher concentrations
of MTA there was not any difference in viability in
response to MTA treatment among cell types harboring
wild type or mutant RAS pathway. However, at lower
concentrations (10 μM) BRAFV600E mutant cells were
slightly more sensitive than wild type or RASQ61L
mutant cell lines.
MTA treatment inhibits melanoma in vivo tumor growth
In view of to the inhibitory capabilities of MTA in vitro,
we tested whether or not MTA was effective inhibiting
in vivo tumor growth. To answer this question we per-
formed an in vivo experiment in a melanoma xenograft
mouse model. The FVB/N syngenic 37-31E melanoma
cell line was subcutaneously injected into FVB/N mice.
Then, mice were divided in two groups and treated with
DMSO (control) and MTA respectively. When tumors
reached between 50-100 mm3 the drug was admini-
strated daily via intraperitoneal letting the tumors grow
for a total of thirty days. Mice treated with MTA
showed a significant decrease (47%) in the tumor
volume (p < 0.001) compared with the controls (DMSO)
(Fig 3A) with no evident toxic effects according to the
mice weight (data not shown) and liver function tests
(ALT(iu/L): control: 19 ± 2; MTA: 18 ± 3; AST(iu/L): con-
trol: 45 ± 4; MTA: 54 ± 3).
We investigated the status of p-Erk1/2, p-Akt and p-
S6 by immunohistochemistry using paraffin-embedded
tumor samples. Tumor samples treated with MTA
showed a diminished activity of the PI3K and mTOR
pathways according to the p-Erk1/2, p-Akt and p-S6
levels (Fig 3B).
Altogether, these results indicate that MTA treatment
is effective blocking melanoma in vivo tumor growth
interfering with the activation of PI3K and mTOR
pathways.
MTA promotes cytostatic effects rather than pro-
apoptotic responses
Several publications have demonstrated both the cyto-
static and pro-apoptotic effects of MTA in mammalian
cells [10,26-28]. In our system, the proliferation curves
and in vivo results suggested that MTA might be
inhibiting cell proliferation and in vivo tumor growth
through cytostatic rather than pro-apoptotic mechan-
isms. To further confirm this hypothesis we analyzed
proliferation markers and the apoptosis levels of the
tumor samples and performed in vitro experiments to
investigate the effects of MTA in promoting apoptosis.
Immunostaining of the tumor tissues showed that
samples from MTA treated mice had lower levels of
cyclin D1 expression that closely correlated with a lower
tumor proliferation index according to the Ki67 immu-
nostaining (Fig 4A). Apoptosis within the tumor was
measured by TUNEL assay and quantification of
cleaved-caspase-3 positive tumor cells in paraffin sec-
tions. Our results showed that MTA-treated samples
had slightly higher levels of apoptotic cells compared
with control tumors (Fig 4B). In addition to this, it is
known that angiogenesis is directly related to tumor
growth. Interestingly, the intra-tumoral expression of
VEGF, as well as the basal expression of VEGF in 37-
31E cells was down regulated by MTA treatment (Fig
4C). Furthermore, these data correlated with a signifi-
cant lower vessel density of MTA-treated tumor samples
according to CD31 staining (Fig 4C).
We further analyzed the effect of MTA in vitro. 37-
31E cells were treated with 10 μM MTA for different
periods of time up to 48 h. At the molecular level the
results showed that p-Bad and cleaved-caspase-3 levels
did not change significantly over time, indicating the
low levels of apoptosis (Fig 4D). However, MTA treat-
ment promoted the de-phosphorylation of the mTOR
downstream target ribosomal protein S6 and the down-
regulation of the cyclin D1 protein levels, supporting the
cytostatic effects of MTA (Fig 4D). Additionally, motility
of 37-31E cells was also significantly reduced upon
MTA treatment (additional file 1, panel B). Importantly,
cell cycle analysis of melanoma cells harboring wild type
RAS and BRAF (37-31E), NRASQ61L mutation
(SKMel147) and BRAFV600E mutation (UACC903) trea-
ted with 10 μM MTA for 48 h, showed an increased
number of cells in G1 phase compared with untreated
cells (6.6% ± 0.8% (p < 0.05), 8.9% ± 0.5% (p < 0.05) and
16.4% ± 0.7% (p < 0.01) respectively) (Fig 4E). Interest-
ingly BRAFV600E mutant cells UACC903 showed the
highest proportion of cells in G1 phase, indicating a slo-
wed down cell cycle
Altogether, these results show evidences indicating
that cytostatic effects on tumor cells mediate the reduc-
tion in melanoma tumor growth upon MTA treatment.
Discussion
Melanoma is the most serious form of skin cancer. If it
is not recognized and treated early, the cancer can
advance and spread to other parts of the body, where it
becomes hard to treat and can be fatal. Recent studies
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Figure 2 Methylthioadenosine (MTA) decreases melanoma cell viability. Clonogenic assays of 37-31E, MeWo, SKMel147, SKMel103, UACC903
and Colo 829 melanoma cells in complete medium with increasing concentrations of Methylthioadenosine (MTA). Three hundred cells were
seeded clones were visualized by crystal violet staining and counted. Fresh media was changed every 48 h. Graphs represent the percentage
reduction in the number of clones upon different treatments. p-value was calculated performing a Wilcoxon-signed rank test (Vassar Stats).
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have provided a much-improved understanding of mela-
noma biology, however, this knowledge has yet to be
translated into effective treatment strategies. In this
study, we investigated the therapeutic capabilities of
MTA in melanoma treatment, a natural occurring
nucleoside that has been shown to be effective in other
tumor types [6,10,16,29,30]. Our results show that MTA
inhibits in vitro cell proliferation, and viability in a dose
dependent manner in a variety of human and mouse
melanoma cell lines. Importantly, MTA treatment was
also effective inhibiting in vivo tumor growth in a
mouse melanoma xenograft model. Furthermore, the
molecular analysis of the tumor samples and experi-
ments performed with the cell lines indicated that in
our model MTA has mostly cytostatic rather that pro-
apoptotic effects.
Besides the inhibitory effects on the polyamine bio-
synthesis, MTA has been shown to exert other potent
and specific pharmacological effects on cellular func-
tions such as proliferation, apoptosis and modulation of
the immune system [10,31,32]. Our current findings are
in agreement with previous publications showing the
inhibitory effects of MTA on proliferation and invasion
(Fig 1 and additional file 1) of different types of tumor
cells lines [33-35]. It is known that genetic mutations
within tumor cells condition the drug response and this
could be taken as an advantage in the design of more
effective therapeutic approaches. Interestingly, BRAF
mutant melanoma cell lines (UACC903 and Colo829)
showed the highest sensitivity to MTA treatment, where
concentrations of 10 μM of MTA reduced proliferation
up to 70% (Fig 1D). Why BRAF mutant cells are more
sensitive to MTA treatment is unknown and is an area
of our current investigation. Nevertheless, the inhibition
of cyclin D1 and proliferation by MTA might have a
more pronounced effect in cells addicted to oncogenes
with potent mitogenic effects. Additionally, the low
levels of MTAP protein expressed in both cell lines
might be contributing to the observed response.
In agreement with the in vitro results, MTA treatment
reduced in vivo tumor growth by 45%. The molecular
analysis of the tumors indicated that MTA treated
Figure 3 Methylthioadenosine (MTA) inhibits in vivo tumor growth and decreases the activation of RAS and PI3K tumor signaling
pathways. (A) 37-31E melanoma cell line was subcutaneously injected into immunocompetent FVB/N mice. The animal groups were treated
with DMSO (Control) (n = 7) or methylthioadenosine (MTA) (n = 7). Tumor size was calculated as described in materials and methods. p-values
were calculated performing a t-student test. Representative photographs of three paired untreated and MTA-treated excised melanoma tumors
are showed on the right. (B) Immunostaining of paraffin-embedded tumor sections showing the levels of p-Erk1/2, p-Akt and p-S6 (20×). Insets
show a 40× detail of the picture. Representative images from two different untreated and treated tumors are shown.
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Figure 4 Methylthioadenosine (MTA) promotes cytostatic effects rather than pro-apoptotic effects in melanoma tumors and cells.
(A) Tumor sections from mice treated either with DMSO or MTA were stained with cyclin D1 and Ki67 antibodies. Representative pictures are
shown. (B) Quantification of apoptotic cells within the tumors. Paraffin-embedded tumor samples were subjected to TUNEL assay or stained
against cleaved caspase-3. Graph shows the quantification of the TUNEL assay. Positive cells from ten fields (20×) per sample were quantified
and the average number of cells per field was calculated. (C) Upper graph, quantification by qRT-PCR of VEGF levels in tumor samples. Lower
graph, qRT-PCR of VEGF expression levels. 37-31E were untreated (Control) or treated for 48 h with 10 μM of MTA in complete medium.
Microvessel’s density quantification in xenografts. Graph shows CD31 fluorescence per μm2. Representative pictures are showed on the right.
p-values were calculated performing a t-student test. (D) 37-31E cells were treated with MTA (10 μM) for the time points indicated. Fifty
micrograms of total lysates were resolved by PAGE-SDS. p-Bad, cleaved-caspase3, p-S6 and cyclin D1 protein levels are showed. GAPDH is used
as a loading control. (E) MTA treatment induces a slowdown cell cycle G1 phase. Cells were grown in complete medium for 48 h in the
presence or absence of MTA (10 μM). Cell cycle analysis was measured in triplicates using Cell Cycle Analysis Guava-Viacount reagent (Guava
Technologies). Average of the three samples in each phase of the cell cycle are shown. p-values were calculated performing a t-student test
(* = p < 0.05; ** = p < 0.01).
Andreu-Pérez et al. BMC Cancer 2010, 10:265
http://www.biomedcentral.com/1471-2407/10/265
Page 8 of 11
tumors had lower rates of proliferation according to the
Ki67 and cyclin D1 levels, that correlated with lower
levels in the PI3K and mTOR pathway activation and
VEGF expression. While several studies have shown
pro-apoptotic effects of MTA in tumor treatment
[10,31], we observed a small increase of apoptosis in our
tumor samples.
Recently, it has been described that MTA was able to
induce the expression of growth factors and matrix
metalloproteases in melanoma cells as well as enhance
invasion and vasculogenic mimicry [5]. It is widely
known that MTA inhibits methyltransferase enzymatic
reactions and interferes with cellular pathways modulat-
ing cell signaling and protein expression [5,14,16,17]. In
the mentioned study, the obtained data was generated at
early time points of MTA treatment. Furthermore, the
biological outcome in a long-term treatment, such as
melanoma cell proliferation and the in vivo melanoma
tumor growth, were not assessed. Our data show that
the inhibitory effects of MTA on melanoma cell prolif-
eration occur mostly after 48 h treatment. We believe
that the biological response to MTA is dose dependent
and cell type dependent. Indeed, several publications
have shown that fibroblasts and normal hepatocytes
have contrary responses to MTA compared to tumor
cells. Moreover, in our system low concentrations of
MTA (1 μM) promoted a slight increase in proliferation
and viability, supporting a possible cell-type specific dif-
ferential response to low concentrations of MTA. In
mice, after intraperitoneal administration at 75 mg/kg,
serum levels of MTA rapidly reached a peak of 28 μM
rapidly and, at 30 minutes MTA was still at 10 μM [12].
In our hands a preliminary study of the bioavailability of
MTA showed that plasma concentrations 20 min after i.
p administration of this compound at 96 μmol/kg
(equivalent to 30 mg/kg) were in the micromolar range
(20-30 μM) (unpublished observations). In view of the
efficacy of MTA reducing in vivo tumor growth, we
speculate that the concentration reached within the
tumor should be higher than 1 μM.
Previous studies have described a cytostatic effect of
MTA on Mewo-LC1, Raji and R1.1 H cells [26-28].
According to our current observations in the xenograft
model, MTA promoted cytostatic rather than pro-apop-
totic effects. This result was confirmed by the in vitro
experiments using the same cell line, where we found
that MTA treatment induced the dephosphorylation of
the downstream mTOR target S6 ribosomal protein, and
the decrease of cyclin D1 protein levels. Importantly, we
did not observe any molecular indication of apoptosis.
Supporting these results, treatment of melanoma cells
with MTA induced a cell cycle slow down in G1 phase.
Interestingly, in agreement with the proliferation and
viability results, UACC903 BRAF mutant melanoma
cells showed the higher accumulation of cells in G1
phase.
MTA is a well-tolerated drug, devoid of the unwanted
effects of other methyltransferase inhibitors. It has been
administered previously in both acute and chronic
experimental models of liver injury and systemic inflam-
mation, showing efficacy and a safe profile [32] with an
ID50 of 2.9-0.4 gm/kg (intramuscular) in rats [13]. In
humans, MTA is also well tolerated [34,35]. Thus, MTA
or any of its synthesized analogs would be good candi-
dates for melanoma treatment in patients
Conclusions
Altogether, here we show the therapeutic potential of
the naturally occurring nucleoside MTA in melanoma
treatment. Importantly, our results demonstrate that
MTA inhibits melanoma cell proliferation and in vivo
tumor growth, supporting the antitumoral potential of
MTA shown by others in other type of tumors. The
data also suggest that BRAFV600E mutant cells appeared
to be more sensitive to the cytostatic effects mediated
by MTA. This study outlines an efficacious and well-
tolerated therapeutic candidate for melanoma
intervention.
Additional material
Additional file 1: Figure S1. A) MTA does not inhibit proliferation
and viability of normal cells (MEFs). Cell proliferation of mouse
embryo fibroblasts (MEFs) in response to increasing concentration of
MTA. Medium was changed adding fresh MTA every 48 h. Proliferation
assays were performed by counting the number of viable cells using
Guava-Viacount reagent (Guava Technologies) in a cell counter (Viacount)
at the time points indicated. Clonogenic assays using MEFs in complete
medium with increasing concentrations of Methylthioadenosine (MTA).
Three hundred cells were seeded. Clones were visualized by crystal violet
staining and counted. Fresh media was changed every 48 h. Graphs
represent the percentage reduction in the number of clones upon
different treatments. p-value was calculated performing a Wilcoxon-
signed rank test (Vassar Stats). (B) MTA inhibits motility of 37-31E
melanoma cells: 37-31 melanoma cells were seeded in a 24 multi-well
plate trans-wells (Corning). Following treatment (either DMSO or MTA
100 μM for the times indicated) cells were washed with PBS and fixed
with 1% glutaraldehyde in PBS. Cells were then stained with an aqueous
solution of 0.1% crystal violet. After destaining in water, non-migrating
cells in the top of the trans-well were removed, and stained migrating
cells in the bottom of the trans-well were destaining with PBS
containing 0.2% Triton X-100. The O.D. was then measured at 590 nm
(Gillies et al., 1986). All the experiments were done in triplicates. p-values
were calculated performing a t-student test (*) = p < 0.01.
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